A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease

Trial Profile

A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Crenezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 26 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 23 Mar 2017 Data from this trial will be presented at the 13th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2017), according to an AC Immune media release.
    • 01 Feb 2016 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top